Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 9. The knockdown of RPL22L1 in A549 cells was found to enhance their proliferation, migration, and invasion. (A) Western blot analysis was conducted to assess the expression of RPL22L1 in LUAD cell lines. (B) The knockdown efficiency of RPL22L1 in A549 cells was evaluated using Western blot analysis. (C) The impact of RPL22L1 knockdown on the viability of A549 cells was determined through a cell viability assay. (D) Cloning experiments were performed to investigate the effect of RPL22L1 knockdown on the proliferation ability of A549 cells. (E, F) The wound healing assay demonstrated the impact of PRL22L1 knockdown on the migratory behavior of A549 cells. (G, H) Transwell assays revealed that RPL22L1 knockdown had the potential to decrease the invasive capabilities of A549 cells. (I) Flow cytometry analysis provided insights into the influence of PRL22L1 knockdown on apoptosis in A549 cells. Statistical significance was denoted by *p < 0.05, **p < 0.01, and ***p < 0.001.